共 19 条
- [1] LYL119, an investigational ROR1-targeted CAR T-cell product incorporating four novel reprogramming technologies designed for effective cell therapy for solid tumorsCANCER RESEARCH, 2024, 84 (06)Lam, Viola C.Li, AileenCasas, Meritxell GalindoBarragan, JessicaCheung, ChristinaBriones, JessicaAfreen, EshaVavra, GrantLu, JiaSundar, PurnimaMartinez, RowenaSims, CandacePotluri, ShobhaAli, OmarCheung, Alexander S.Lynn, Rachel C.
- [2] Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid TumorsMOLECULAR THERAPY, 2022, 30 (04) : 311 - 311Park, SpencerWang, XiaoSimianer, CourtneySpadinger, SydneySharma, NeerajLu, JiaRyu, ByoungSong, LisaWeitzner, BrianMoffett, HowellLajoie, MarcBoyken, ScottVong, QueenieSundar, PurnimaVodnala, SumanHiraragi, HajimeBoldajipour, BijanLynn, RachelPotluri, ShobhaSather, Blythe
- [3] Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumorsANNALS OF ONCOLOGY, 2022, 33 (07) : S896 - S896Spigel, D. R.Murthy, H.Chumsri, S.Ganguly, B. J.Gong, L.Hiraragi, H.Larsen, E.Liu, W.Martell, L.Zhu, S.Bornman, I-M.Fitzsimmons, S.Barnum, E.Christiansen, S.Gillenwater, H.
- [4] LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumorsCANCER RESEARCH, 2022, 82 (12)Park, SpencerSimianer, CourtneySpadinger, SydneyWang, XiaoSundar, PurnimaPotluri, ShobhaLynn, RachelBoldajipour, BijanWang, GraceSharma, NeerajHiraragi, HajimeKrishnamoorthy, VeenaVodnala, Suman KumarOng, E-ChingWu, Chang-ChihWohlfahrt, MartinRyu, ByoungSong, LisaWeitzner, Brian D.Moffett, HowellLajoie, MarcBoyken, ScottShabaneh, TamerSrivastava, ShivaniAlbertson, TinaSather, Blythe
- [5] Tumor-Targeted Radiation Therapy Helps Overcome the Solid Tumor T-Cell Infiltration Barrier and Promotes Mesothelin CAR T-Cell TherapyJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S228 - S228Mayor, MarissaVillena-Vargas, JonathanDe Biasi, AndreasMorello, AuroreJones, David R.Sadelain, MichelAdusumilli, Prasad S.
- [6] A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical DevelopmentCANCER DISCOVERY, 2023, 13 (09) : 1982 - 1997Dickinson, Michael J.Barba, PereJaeger, UlrichShah, Nirav N.Blaise, DidierBriones, JavierShune, LeylaBoissel, NicolasBondanza, AttilioMariconti, LuisaMarchal, Anne-LaureQuinn, David S.Yang, JenniferPrice, AndrewSohoni, AkashTreanor, Louise M.Orlando, Elena J.Mataraza, JenniferDavis, JaclynLu, DarleneZhu, XuEngels, BorisMoutouh-de Parseval, LaureBrogdon, Jennifer L.Moschetta, MicheleFlinn, Ian W.
- [7] PD-1 Ligands are Upregulated after T-Cell Attack in Childhood Solid Tumors and May Become a Candidate for CAR-T Cell TherapyPEDIATRIC BLOOD & CANCER, 2018, 65 : S78 - S79Shin, ChansuKubo, NobuhiroKasahara, YasushiIwabuchi, HarukoImamura, MasaruSaitoh, AkihikoImai, Chihaya
- [8] Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignanciesTRANSLATIONAL RESEARCH, 2017, 187 : 11 - 21Chen, DavidYang, James
- [9] Preclinical development of novel humanised ROR1 targeting chimeric antigen receptor T cells and bispecific T-cell engagersLANCET, 2017, 389 : 40 - 40Gohil, SatyenParedes-Moscosso, SolangeHarrasser, MicaelaDavidoff, AndrewPule, MartinDella Peruta, MarcoNathwani, Amit
- [10] T Cells Expressing a Modified FcgRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid TumorsCANCER IMMUNOLOGY RESEARCH, 2023, 11 (06) : 792 - 809Rasoulouniriana, DianaSantana-Magal, NadineGutwillig, AmitFarhat-Younis, LeenTal, LiorAmar, SarahMilyavsky, MichaelMuddineni, Siva Sai Naga AnuragMuddineni, AnuragSolomon, NetaShpilt, HanaDotan, ShaharPilpel, NoamWaskow, ClaudiaFeinmesser, MeoraRider, PelegCarmi, Yaron